Manufacturer of Controlled Substances; Notice of Registration; Cedarburg Pharmaceuticals, Inc., 30028 [2012-12271]
Download as PDF
<![CDATA[
30028
Federal Register / Vol. 77, No. 98 / Monday, May 21, 2012 / Notices
The company plans to manufacture the
listed controlled substances in bulk for
distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Siegfried (USA), to manufacture the
listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Siegfried (USA), to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR
§ 1301.33, the above named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed.
Dated: May 11, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
BILLING CODE 4410–09–P
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Cedarburg Pharmaceuticals, Inc.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Cambrex Charles City, Inc.
By Notice dated September 27, 2011,
and published in the Federal Register
on October 7, 2011, 76 FR 62449,
Cambrex Charles City, Inc., 1205 11th
Street, Charles City, Iowa 50616, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
Schedule
ebenthall on DSK5SPTVN1PROD with NOTICES
Noroxymorphone (9668) ..............
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
II
II
II
The company plans to manufacture
the listed controlled substance
Noroxymorphone (9668), in bulk for
sale to its customers. It plans to
manufacture the other two listed
controlled substances in bulk for dosage
form development, clinical trials, and
use in stability qualification studies.
No comments or objections have been
received. DEA has considered the
Jkt 226001
By Notice dated January 6, 2012, and
published in the Federal Register on
January 17, 2012, 77 FR 2324, Cedarburg
Pharmaceuticals, Inc., 870 Badger
Circle, Grafton, Wisconsin 53024, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
Schedule
4-Anilino-N-phenethyl-4-piperidine
(8333).
Fentanyl (9801) ............................
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
Regarding the drug code (8333), the
company plans to use this controlled
substance to manufacture another
controlled substance.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cedarburg Pharmaceuticals, Inc. to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
investigated Cedarburg Pharmaceuticals,
Inc. to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: May 11, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–12271 Filed 5–18–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Johnson Matthey, Inc.,
Pharmaceuticals Materials
DEPARTMENT OF JUSTICE
BILLING CODE 4410–09–P
18:18 May 18, 2012
Dated: May 11, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–12275 Filed 5–18–12; 8:45 am]
[FR Doc. 2012–12274 Filed 5–18–12; 8:45 am]
VerDate Mar<15>2010
factors in 21 U.S.C. 823(a), and
determined that the registration of
Cambrex Charles City, Inc. to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Cambrex Charles City, Inc.
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
By Notice dated January 6, 2012, and
published in the Federal Register on
January 17, 2012, 77 FR 2324, Johnson
Matthey, Inc., Pharmaceuticals
Materials, 900 River Road,
Conshohocken, Pennsylvania 19428,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
Drug
Gamma
Hydroxybutyric
Acid
(2010).
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Codeine (9050) .............................
Oxycodone (9143) ........................
Hydrocodone (9193) .....................
Morphine (9300) ...........................
Thebaine (9333) ...........................
Schedule
I
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for sale to its customers. The Thebaine
(9333) will also be used to manufacture
other controlled substances in bulk
which will also be for sale in bulk to its
customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Johnson Matthey Inc., Pharmaceuticals
Materials to manufacture the listed basic
E:\FR\FM\21MYN1.SGM
21MYN1
]]>Agencies
[Federal Register Volume 77, Number 98 (Monday, May 21, 2012)]
[Notices]
[Page 30028]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-12271]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration;
Cedarburg Pharmaceuticals, Inc.
By Notice dated January 6, 2012, and published in the Federal
Register on January 17, 2012, 77 FR 2324, Cedarburg Pharmaceuticals,
Inc., 870 Badger Circle, Grafton, Wisconsin 53024, made application by
renewal to the Drug Enforcement Administration (DEA) to be registered
as a bulk manufacturer of the following basic classes of controlled
substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
4-Anilino-N-phenethyl-4-piperidine (8333).. II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for distribution to its customers. Regarding the drug code
(8333), the company plans to use this controlled substance to
manufacture another controlled substance.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Cedarburg Pharmaceuticals, Inc. to manufacture the listed basic classes
of controlled substances is consistent with the public interest at this
time. DEA has investigated Cedarburg Pharmaceuticals, Inc. to ensure
that the company's registration is consistent with the public interest.
The investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with state and local laws, and a review of the company's background and
history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance
with 21 CFR 1301.33, the above named company is granted registration as
a bulk manufacturer of the basic classes of controlled substances
listed.
Dated: May 11, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2012-12271 Filed 5-18-12; 8:45 am]
BILLING CODE 4410-09-P
